Form 4 for MGNX MACROGENICS INC
Accepted 2024-03-08 00:00:00 ET · period of report 2024-03-06 · accession 0001125345-24-000063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-08 | 2024-03-06 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $10.90 | +19.6K | 19.8K | +13,534% | +$213.9K |
| D | 2024-03-08 | 2024-03-06 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | S - Sale+OE | $21.50 | -19.6K | 8,895 | -69% | -$421.9K |
| DM | 2024-03-08 | 2024-03-06 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $10.90 | -19.6K | 39.4K | -33% | -$213.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-06 | M | A | 8,750 | $10.15 | 28,520 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-06 | S | D | 19,625 | $21.50 | 8,895 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022. |
| 3 | Common | Common Stock | 2024-03-06 | M | A | 10,875 | $11.50 | 19,770 | D | — | — | |
| 4 | Derivative | Employee stock option (right to buy) | 2024-03-06 | M | D | 10,875 | $11.50 | 0 | D | $11.50 · — to 2030-02-20 | 10,875 Common Stock | (F2) 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |
| 5 | Derivative | Employee stock option (right to buy) | 2024-03-06 | M | D | 8,750 | $10.15 | 39,375 | D | $10.15 · — to 2032-02-22 | 8,750 Common Stock | (F2) 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. |